Compile Data Set for Download or QSAR
Report error Found 135 Enz. Inhib. hit(s) with all data for entry = 9281
TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455296(US10730875, Compound 1 | US10730875, Compound 13)
Affinity DataIC50: 500nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455311(US10730875, Compound 11)
Affinity DataIC50: 500nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455314(US10730875, Compound 14)
Affinity DataIC50: 500nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455315(US10730875, Compound 16)
Affinity DataIC50: 500nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455316(US10730875, Compound 17)
Affinity DataIC50: 500nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455322(US10730875, Compound 24)
Affinity DataIC50: 500nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455324(US10730875, Compound 26)
Affinity DataIC50: 500nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455326(US10730875, Compound 28)
Affinity DataIC50: 500nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455328(US10730875, Compound 30)
Affinity DataIC50: 500nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455328(US10730875, Compound 30)
Affinity DataIC50: 500nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455330(US10730875, Compound 32)
Affinity DataIC50: 500nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455296(US10730875, Compound 1 | US10730875, Compound 13)
Affinity DataIC50: 500nMAssay Description:To assay JAK1 inhibition, 2 μL of IL-6 diluted at 400 ng/mL (4×) in HBSS containing 0.1% BSA was added to the treated cells. The cells were then...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455314(US10730875, Compound 14)
Affinity DataIC50: 500nMAssay Description:To assay JAK1 inhibition, 2 μL of IL-6 diluted at 400 ng/mL (4×) in HBSS containing 0.1% BSA was added to the treated cells. The cells were then...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455316(US10730875, Compound 17)
Affinity DataIC50: 500nMAssay Description:To assay JAK1 inhibition, 2 μL of IL-6 diluted at 400 ng/mL (4×) in HBSS containing 0.1% BSA was added to the treated cells. The cells were then...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455322(US10730875, Compound 24)
Affinity DataIC50: 500nMAssay Description:To assay JAK1 inhibition, 2 μL of IL-6 diluted at 400 ng/mL (4×) in HBSS containing 0.1% BSA was added to the treated cells. The cells were then...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455324(US10730875, Compound 26)
Affinity DataIC50: 500nMAssay Description:To assay JAK1 inhibition, 2 μL of IL-6 diluted at 400 ng/mL (4×) in HBSS containing 0.1% BSA was added to the treated cells. The cells were then...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455326(US10730875, Compound 28)
Affinity DataIC50: 500nMAssay Description:To assay JAK1 inhibition, 2 μL of IL-6 diluted at 400 ng/mL (4×) in HBSS containing 0.1% BSA was added to the treated cells. The cells were then...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455328(US10730875, Compound 30)
Affinity DataIC50: 500nMAssay Description:To assay JAK1 inhibition, 2 μL of IL-6 diluted at 400 ng/mL (4×) in HBSS containing 0.1% BSA was added to the treated cells. The cells were then...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455299(US10730875, Compound 4)
Affinity DataIC50: 750nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455307(US10730875, Compound 7)
Affinity DataIC50: 750nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455308(US10730875, Compound 8)
Affinity DataIC50: 750nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455296(US10730875, Compound 1 | US10730875, Compound 13)
Affinity DataIC50: 750nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455321(US10730875, Compound 23)
Affinity DataIC50: 750nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455325(US10730875, Compound 27)
Affinity DataIC50: 750nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455326(US10730875, Compound 28)
Affinity DataIC50: 750nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455326(US10730875, Compound 28)
Affinity DataIC50: 750nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455328(US10730875, Compound 30)
Affinity DataIC50: 750nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455329(US10730875, Compound 31)
Affinity DataIC50: 750nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455296(US10730875, Compound 1 | US10730875, Compound 13)
Affinity DataIC50: 3.00E+3nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455296(US10730875, Compound 1 | US10730875, Compound 13)
Affinity DataIC50: 3.00E+3nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455298(US10730875, Compound 3)
Affinity DataIC50: 3.00E+3nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455306(US10730875, Compound 6)
Affinity DataIC50: 3.00E+3nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455309(US10730875, Compound 9)
Affinity DataIC50: 3.00E+3nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455310(US10730875, Compound 10)
Affinity DataIC50: 3.00E+3nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455312(US10730875, Compound 12)
Affinity DataIC50: 3.00E+3nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455314(US10730875, Compound 14)
Affinity DataIC50: 3.00E+3nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455314(US10730875, Compound 14)
Affinity DataIC50: 3.00E+3nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455316(US10730875, Compound 17)
Affinity DataIC50: 3.00E+3nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455316(US10730875, Compound 17)
Affinity DataIC50: 3.00E+3nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455322(US10730875, Compound 24)
Affinity DataIC50: 3.00E+3nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455322(US10730875, Compound 24)
Affinity DataIC50: 3.00E+3nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455296(US10730875, Compound 1 | US10730875, Compound 13)
Affinity DataIC50: 5.00E+3nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455298(US10730875, Compound 3)
Affinity DataIC50: 5.00E+3nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455298(US10730875, Compound 3)
Affinity DataIC50: 5.00E+3nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455298(US10730875, Compound 3)
Affinity DataIC50: 5.00E+3nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455299(US10730875, Compound 4)
Affinity DataIC50: 5.00E+3nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455299(US10730875, Compound 4)
Affinity DataIC50: 5.00E+3nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455299(US10730875, Compound 4)
Affinity DataIC50: 5.00E+3nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455305(US10730875, Compound 5)
Affinity DataIC50: 5.00E+3nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Jn Therapeutics

US Patent
LigandPNGBDBM455305(US10730875, Compound 5)
Affinity DataIC50: 5.00E+3nMAssay Description:The in vitro inhibition of recombinant human JAKs was determined as follow.Compounds were tested in LANTHASCREEN time-resolved fluorescence energy tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
Go to US Patent

Displayed 1 to 50 (of 135 total ) | Next | Last >>
Jump to: